Myriad Genetics Inc. (NASDAQ:MYGN) went down by -7.23% from its latest closing price compared to the recent 1-year high of $31.60. The company’s stock price has collected -1.38% of loss in the last five trading sessions. Press Release reported 13 hours ago that Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services
Is It Worth Investing in Myriad Genetics Inc. (NASDAQ :MYGN) Right Now?
Plus, the 36-month beta value for MYGN is at 1.64. Opinions of the stock are interesting as 1 analysts out of 9 who provided ratings for Myriad Genetics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 4 rated it as “hold,” and 3 as “sell.”
The average price from analysts is $25.25, which is -$2.63 below the current price. MYGN currently public float of 73.21M and currently shorts hold a 6.88% ratio of that float. Today, the average trading volume of MYGN was 883.41K shares.
MYGN’s Market Performance
MYGN stocks went down by -1.38% for the week, with a monthly jump of 3.92% and a quarterly performance of 61.02%, while its annual performance rate touched 58.53%. The volatility ratio for the week stands at 8.20% while the volatility levels for the past 30 days are set at 6.46% for Myriad Genetics Inc.. The simple moving average for the period of the last 20 days is -3.79% for MYGN stocks with a simple moving average of 69.65% for the last 200 days.
Analysts’ Opinion of MYGN
Many brokerage firms have already submitted their reports for MYGN stocks, with BofA/Merrill repeating the rating for MYGN by listing it as a “Underperform.” The predicted price for MYGN in the upcoming period, according to BofA/Merrill is $28 based on the research report published on September 26th of the previous year 2019.
Piper Jaffray, on the other hand, stated in their research note that they expect to see MYGN reach a price target of $40, previously predicting the price at $45. The rating they have provided for MYGN stocks is “Neutral” according to the report published on August 14th, 2019.
MYGN Trading at 11.62% from the 50-Day Moving Average
After a stumble in the market that brought MYGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.40% of loss for the given period.
Volatility was left at 6.46%, however, over the last 30 days, the volatility rate increased by 8.20%, as shares surge +0.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +60.57% upper at present.
During the last 5 trading sessions, MYGN fell by -1.38%, which changed the moving average for the period of 200-days by +100.49% in comparison to the 20-day moving average, which settled at $29.77. In addition, Myriad Genetics Inc. saw 44.78% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at MYGN starting from LANCHBURY JERRY S, who sale 80,000 shares at the price of $29.71 back on Feb 16. After this action, LANCHBURY JERRY S now owns 246,575 shares of Myriad Genetics Inc., valued at $2,377,048 using the latest closing price.
Parkinson Paul, the EVP Strategy and Innovation of Myriad Genetics Inc., sale 11,824 shares at $25.00 during a trade that took place back on Jan 08, which means that Parkinson Paul is holding 76,746 shares at $295,600 based on the most recent closing price.
Stock Fundamentals for MYGN
Current profitability levels for the company are sitting at:
- -21.11 for the present operating margin
- +61.31 for the gross margin
The net margin for Myriad Genetics Inc. stands at -31.24. The total capital return value is set at -10.63, while invested capital returns managed to touch -15.82. Equity return is now at value -20.60, with -13.60 for asset returns.
Based on Myriad Genetics Inc. (MYGN), the company’s capital structure generated 32.11 points at debt to equity in total, while total debt to capital is 24.30. Total debt to assets is 19.09, with long-term debt to equity ratio resting at 30.64. Finally, the long-term debt to capital ratio is 23.19.
When we switch over and look at the enterprise to sales, we see a ratio of 1.44, with the company’s debt to enterprise value settled at 0.32. The receivables turnover for the company is 6.09 and the total asset turnover is 0.40. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.26.